NASDAQ:VBIO
Valion Bio, Inc.
Valion Bio, Inc. reported net income of −$8.9M in fiscal 2025. Free cash flow was −$7.0M.Summary generated from Valion Bio, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−91.8%
Debt / equityn/a
Free cash flow−$7.0M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 2 | 1 | 1 | n/a |
| Operating income | −6 | −10 | −8 | −4 | −8 |
| Net income | −8 | −10 | −8 | −6 | −9 |
| Free cash flow | n/a | −9 | −9 | −6 | −7 |
Recent filings
- 8-KEntry into a material agreement
Oct 8, 2026 - 8-KOther events
Oct 6, 2026 - 8-KOther events
Oct 1, 2026 - 4Insider transaction report
Sep 24, 2026 - 4Insider transaction report
Sep 24, 2026 - 8-KDirector or officer change
Sep 23, 2026 - 8-KEntry into a material agreement
Sep 1, 2026 - 8-KAmendment to articles or bylaws
Aug 27, 2026